Search

Repligen Corp

Chiusa

SettoreSettore sanitario

132.37 -3.86

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

131.74

Massimo

134.28

Metriche Chiave

By Trading Economics

Entrata

-5M

8.3M

Vendite

-3.7M

194M

P/E

Media del settore

159.879

62.58

EPS

0.48

Margine di Profitto

4.29

Dipendenti

2,000

EBITDA

-13M

32M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+25.31% upside

Dividendi

By Acuity

Utili prossimi

28 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.5B

8.2B

Apertura precedente

136.23

Chiusura precedente

132.37

Notizie sul Sentiment di mercato

By Acuity

25%

75%

51 / 340 Classifica in Healthcare

Repligen Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 lug 2026, 19:06 UTC

News

Repligen Corp is under scrutiny as a stock to avoid, with concerns over its $763.3 million revenue and declining operating margins. Shares are trading lower today.

22 lug 2026, 19:25 UTC

News
Event
Social Media

Repligen Corp is acquiring BioLife Solutions for about $1.5 billion, offering $11.25 in cash and stock, with a projected $20 million in synergies.

21 lug 2026, 22:56 UTC

Repligen Corp shares are higher in after-market trading, despite a recent trend of lower closes. Broader market sentiment may be influenced by the Nikkei 225 surge.

20 lug 2026, 18:06 UTC

Repligen Corp shares are higher today, reflecting positive market sentiment despite earlier intraday fluctuations. No specific news was identified to explain the movement.

Confronto tra pari

Modifica del prezzo

Repligen Corp Previsione

Obiettivo di Prezzo

By TipRanks

25.31% in crescita

Previsioni per 12 mesi

Media 165.36 USD  25.31%

Alto 207 USD

Basso 142 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Repligen Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

11

Acquista

3

Mantieni

0

Vendi

Sentiment

By Acuity

51 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat